Company Overview
Snapshot
Founded in March 1997, Se-cure Pharmaceuticals operates with 11–50 employees. The company has raised $14 million across one funding round from 5 investors. In December 2017, the company launched a new women's supplement line in the U.S.
Business overview
Se-cure Pharmaceuticals is a clinical-stage, technology-driven pharmaceutical company specializing in the development of therapeutic solutions derived from botanical sources. The company utilizes proprietary botanical drug development and scaling technologies to introduce novel biochemical agents with selective mechanisms of action. Adhering to US FDA botanical drug development guidelines, Se-cure establishes human and post-marketing data through over-the-counter pilot sales of its botanical therapeutics. Its pipeline includes six botanical drug candidates targeting women's health, osteoporosis management, men's health, benign hyperplasia management, burn injury management, and dental bone rejuvenation. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving markets in the United States and Norway.
Strategic signal
In December 2017, Se-cure Pharmaceuticals launched a new women's supplement line, Femarelle, in the U.S. market. This strategic move indicates the company's focus on expanding its product offerings and market reach within women's health, leveraging its botanical drug development expertise for commercial applications.
Log in to access full profile ›Company Intelligence Q&A
- When was Se-cure Pharmaceuticals founded?
- Se-cure Pharmaceuticals was founded in March 1997.
- What is Se-cure Pharmaceuticals' primary focus?
- Se-cure Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing safe and effective therapeutic solutions derived from botanical sources, adhering to US FDA botanical drug development guidelines.
- What significant product launch did Se-cure Pharmaceuticals undertake?
- In December 2017, Se-cure Pharmaceuticals launched a new women's supplement line, Femarelle, in the U.S. market.
- What is the total disclosed funding raised by Se-cure Pharmaceuticals?
- Se-cure Pharmaceuticals has raised $14 million in total disclosed funding.
- Which markets does Se-cure Pharmaceuticals serve?
- Se-cure Pharmaceuticals serves geomarkets including the United States and Norway.